{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:05:51Z","timestamp":1777946751104,"version":"3.51.4"},"reference-count":80,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1111\/ane.12629","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T06:38:53Z","timestamp":1467355133000},"page":"148-160","source":"Crossref","is-referenced-by-count":34,"title":["The mechanisms of sudden-onset type adverse reactions to oseltamivir"],"prefix":"10.1155","volume":"135","author":[{"given":"R.","family":"Hama","sequence":"first","affiliation":[{"name":"Non-Profit Organization \u201cJapan Institute of Pharmacovigilance\u201d; Tennoji-ku Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Center for Medication Safety and Efficacy; University of South Carolina; College of Pharmacy Member; Hollings National Cancer Institute; Center for Medication Safety and Efficacy; University of South Carolina; Hollings National Cancer Institute; Medical University of South Carolina; Columbia and Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"10.1111\/ane.12629-BIB0001|ane12629-cit-0001","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of\u00a0influenza- recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"10.1111\/ane.12629-BIB0002|ane12629-cit-0002","unstructured":"Antiviral Drugs-Information for Health Care professionals (for the 2015-2016 influenza season) http:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/index.htm"},{"key":"10.1111\/ane.12629-BIB0003|ane12629-cit-0003","unstructured":"World Health Organization WHO Model List of Essential Medicines 19th edition 2015 http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML2015_8-May-15.pdf?ua=1"},{"key":"10.1111\/ane.12629-BIB0004|ane12629-cit-0004","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/bmj.39240.497025.80","article-title":"Tamiflu and neuropsychiatric disturbance in adolescents","volume":"334","author":"Maxwell","year":"2007","journal-title":"BMJ"},{"key":"10.1111\/ane.12629-BIB0005|ane12629-cit-0005","unstructured":"Hama R Discussion of the causal relationship between oseltamivir phosphate (Tamiflu), and sudden death and death from abnormal behaviour (presentation at a session of Japanese Society for Pediatric Infectious Diseases in Tsu, Mie Prefecture November 12, 2005) 2005 http:\/\/www.npojip.org\/english\/no59.html"},{"key":"10.1111\/ane.12629-BIB0006|ane12629-cit-0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JRS-2008-0431","article-title":"Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships","volume":"20","author":"Hama","year":"2008","journal-title":"Int J Risk Saf Med"},{"key":"10.1111\/ane.12629-BIB0007|ane12629-cit-0007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/bmj.39262.448877.BE","article-title":"Oseltamivir's adverse reactions: Fifty sudden deaths may be related to central suppression","volume":"335","author":"Hama","year":"2007","journal-title":"BMJ"},{"key":"10.1111\/ane.12629-BIB0008|ane12629-cit-0008","first-page":"23","article-title":"The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons","volume":"9","author":"Blumentals","year":"2007","journal-title":"MedGenMed"},{"key":"10.1111\/ane.12629-BIB0009|ane12629-cit-0009","doi-asserted-by":"crossref","first-page":"1097114","DOI":"10.2165\/0002018-200831120-00006","article-title":"Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review","volume":"31","author":"Toovey","year":"2008","journal-title":"Drug Saf"},{"key":"10.1111\/ane.12629-BIB0010|ane12629-cit-0010","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1442-200x.2005.02088.x","article-title":"Oseltamivir phosphate in infants under 1 year of age with influenza infection","volume":"47","author":"Tamura","year":"2005","journal-title":"Pediatr Int"},{"key":"10.1111\/ane.12629-BIB0011|ane12629-cit-0011","unstructured":"Shalabi M Abughali N Abzug M Safety of oseltamivir vs. amantadine of rimantadine in children under 1 year of age [Abstract]"},{"key":"10.1111\/ane.12629-BIB0012|ane12629-cit-0012","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1097\/01.inf.0000164799.33635.fe","article-title":"Experience with oseltamivir for infants younger than 1 year old in Japan","volume":"24","author":"Okamoto","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1111\/ane.12629-BIB0013|ane12629-cit-0013","doi-asserted-by":"crossref","first-page":"512","DOI":"10.7326\/0003-4819-156-7-201204030-00411","article-title":"Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies","volume":"156","author":"Hsu","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1111\/ane.12629-BIB0014|ane12629-cit-0014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/jis726","article-title":"Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-10 influenza A(H1N1) pandemic: a systematic review and metaanalysis in hospitalized patients","volume":"207","author":"Muthuri","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1111\/ane.12629-BIB0015|ane12629-cit-0015","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/ane.12629-BIB0016|ane12629-cit-0016","first-page":"1545","article-title":"Epidemiologic survey of influenza-associated complications- I. Clinical assessment of symptoms and signs, and medication","volume":"111","author":"Yokota","year":"2007","journal-title":"J Japan Pediatr Soc"},{"key":"10.1111\/ane.12629-BIB0017|ane12629-cit-0017","first-page":"1559","article-title":"Epidemiologic survey of influenza-associated complications- II. A statistical analysis of symptoms and signs, and medication","volume":"111","author":"Fujita","year":"2007","journal-title":"J Japan Pediatr Soc"},{"key":"10.1111\/ane.12629-BIB0018|ane12629-cit-0018","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3820\/jjpe.15.73","article-title":"A pharmacoepidemiological study on the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza infection","volume":"15","author":"Fujita","year":"2010","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"10.1111\/ane.12629-BIB0019|ane12629-cit-0019","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/EDE.0b013e3181a3d3f6","article-title":"Oseltamivir and abnormal behaviors: true or not?","volume":"20","author":"Yorifuji","year":"2009","journal-title":"Epidemiology"},{"key":"10.1111\/ane.12629-BIB0020|ane12629-cit-0020","unstructured":"Fujiwara F Ikushima S Hibi N An observational study to assess risk factors of abnormal behaviours during influenza"},{"key":"10.1111\/ane.12629-BIB0021|ane12629-cit-0021","unstructured":"Hama R Jones M Hayashi K Yanagi T Sakaguchi K Oseltamivir: A systematic review and meta-analysis of adverse effects in prospective cohort studies (a preliminary report was presented at the 16th\u00a0JSPE and 5th ACPE joint meeting Tokyo 29-30th 2010 Tokyo)"},{"key":"10.1111\/ane.12629-BIB0022|ane12629-cit-0022","unstructured":"Jefferson T Jones MA Doshi P Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children"},{"key":"10.1111\/ane.12629-BIB0023|ane12629-cit-0023","unstructured":"MHLW Documents for the 2014 advisory Panel on Drug Safety (held on 29\/Oct\/2015): Use of drugs for influenza http:\/\/www.mhlw.go.jp\/file\/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka\/0000063406.pdf"},{"key":"10.1111\/ane.12629-BIB0024|ane12629-cit-0024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3233\/JRS-2011-0545","article-title":"Oseltamivir and early deterioration leading to death","volume":"23","author":"Hama","year":"2011","journal-title":"Int J Risk Saf Med"},{"key":"10.1111\/ane.12629-BIB0025|ane12629-cit-0025","unstructured":"Rxisk.org http:\/\/rxisk.org\/drugs-a-z\/"},{"key":"10.1111\/ane.12629-BIB0026|ane12629-cit-0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)60085-X","article-title":"Experimental and Clinical Aspects of Drug Toxicity","volume":"2","author":"Zbinden","year":"1963","journal-title":"Adv Pharmacol"},{"key":"10.1111\/ane.12629-BIB0027|ane12629-cit-0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ilar.43.4.244","article-title":"Guidelines for the design and statistical analysis of experiments using laboratory animals","volume":"43","author":"Festing","year":"2002","journal-title":"ILAR J"},{"key":"10.1111\/ane.12629-BIB0028|ane12629-cit-0028","doi-asserted-by":"crossref","unstructured":"Matsumoto K Yoshimura I Toxicity study and selection of statistical methods in Yoshimura and Ohashi 1992","DOI":"10.7209\/tanso.1992.51"},{"key":"10.1111\/ane.12629-BIB0029|ane12629-cit-0029","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for Industry-Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005 http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM078932.pdf"},{"key":"10.1111\/ane.12629-BIB0030|ane12629-cit-0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1124\/dmd.107.017699","article-title":"Oseltamivir\u00a0(Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein","volume":"36","author":"Morimoto","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/ane.12629-BIB0031|ane12629-cit-0031","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/dmd.107.018556","article-title":"P-glycoprotein restricts the penetration of\u00a0oseltamivir\u00a0across the blood-brain barrier","volume":"36","author":"Ose","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/ane.12629-BIB0032|ane12629-cit-0032","unstructured":"MHLW Documents, advisory Panel on Drug Safety http:\/\/www.mhlw.go.jp\/shingi\/2007\/04\/s0404-2.html"},{"key":"10.1111\/ane.12629-BIB0033|ane12629-cit-0033","unstructured":"MHLW Documents, advisory Panel on Drug Safety http:\/\/www.mhlw.go.jp\/shingi\/2007\/12\/s1225-7.html"},{"key":"10.1111\/ane.12629-BIB0034|ane12629-cit-0034","unstructured":"Chugai Pharm Co Summary basis of approval (SBA) of Tamiflu 2000 http:\/\/www.pmda.go.jp\/drugs\/2000\/g001202\/index.html"},{"key":"10.1111\/ane.12629-BIB0035|ane12629-cit-0035","unstructured":"Chugai Pharm Co SBA of Tamiflu dry syrup 2002 http:\/\/www.pmda.go.jp\/drugs\/2002\/P200200011\/index.html"},{"key":"10.1111\/ane.12629-BIB0036|ane12629-cit-0036","unstructured":"Chugai Pharm Co SBA of Tamiflu capsule 75 for prophylaxis 2004 http:\/\/www.pmda.go.jp\/drugs\/2004\/P200400015\/index.html"},{"key":"10.1111\/ane.12629-BIB0037|ane12629-cit-0037","unstructured":"Examination results by PMDA Tamiflu capsule http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6250021M1"},{"key":"10.1111\/ane.12629-BIB0038|ane12629-cit-0038","unstructured":"Examination results by PMDA Tamiflu dry syrup http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6250021R1"},{"key":"10.1111\/ane.12629-BIB0039|ane12629-cit-0039","unstructured":"Full prescription information of oseltamivir http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021087s07lbl.pdf"},{"key":"10.1111\/ane.12629-BIB0040|ane12629-cit-0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00228-012-1315-5","article-title":"The effect of\u00a0carboxylesterase\u00a01 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans","volume":"69","author":"Suzaki","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/ane.12629-BIB0041|ane12629-cit-0041","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.00588-08","article-title":"Pharmacokinetics of high-dose oseltamivir in healthy volunteers","volume":"53","author":"Wattanagoon","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ane.12629-BIB0042|ane12629-cit-0042","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"Hayden","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/ane.12629-BIB0043|ane12629-cit-0043","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1124\/mol.107.036889","article-title":"Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2","volume":"72","author":"Yang","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1111\/ane.12629-BIB0044|ane12629-cit-0044","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1471-4159.2007.04644.x","article-title":"Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein","volume":"102","author":"Seelbach","year":"2007","journal-title":"J Neurochem"},{"key":"10.1111\/ane.12629-BIB0045|ane12629-cit-0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0006-2952(03)00340-X","article-title":"Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT","volume":"66","author":"Th\u00e9ron","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/ane.12629-BIB0046|ane12629-cit-0046","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/17425255.4.10.1245","article-title":"A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain","volume":"4","author":"Roberts","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/ane.12629-BIB0047|ane12629-cit-0047","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/pr.107.07109","article-title":"Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy","volume":"60","author":"Miller","year":"2008","journal-title":"Pharmacol Rev"},{"key":"10.1111\/ane.12629-BIB0048|ane12629-cit-0048","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcp.2008.10.005","article-title":"Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin","volume":"77","author":"Yang","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/ane.12629-BIB0049|ane12629-cit-0049","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000047185","article-title":"P-glycoprotein expression in mouse brain increases with maturation","volume":"81","author":"Tsai","year":"2002","journal-title":"Biol Neonate"},{"key":"10.1111\/ane.12629-BIB0050|ane12629-cit-0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3923\/ijv.2009.119.130","article-title":"Oseltamivir is devoid of specific behavioral and other central nervous system effects in juvenile rats at supratherapeutic oral doses","volume":"5","author":"Freichel","year":"2009","journal-title":"Int J Virol"},{"key":"10.1111\/ane.12629-BIB0051|ane12629-cit-0051","unstructured":"F. Hofman-La-Roche, Ltd An oral (gavage) toxicity study of Tamiflu (oseltamivir phosphate) in juvenile rats 2007"},{"key":"10.1111\/ane.12629-BIB0052|ane12629-cit-0052","unstructured":"F. Hofman-La-Roche, Ltd Toxicokinetic phase report for the final study report of Tamiflu (oseltamivir phosphate) in juvenile rats 2007"},{"issue":"Suppl A","key":"10.1111\/ane.12629-BIB0053|ane12629-cit-0053","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1053\/plac.2002.0948","article-title":"Cytokines, prostaglandins and parturition-a review","volume":"24","author":"Keelan","year":"2003","journal-title":"Placenta"},{"key":"10.1111\/ane.12629-BIB0054|ane12629-cit-0054","volume-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"Hardeman","year":"2001","edition":"10"},{"key":"10.1111\/ane.12629-BIB0055|ane12629-cit-0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1248\/bpb.31.638","article-title":"Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice","volume":"31","author":"Ono","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"10.1111\/ane.12629-BIB0056|ane12629-cit-0056","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bcpt.12058","article-title":"Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice","volume":"113","author":"Ono","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/ane.12629-BIB0057|ane12629-cit-0057","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1742-7843.2012.00861.x","article-title":"Absence of central nervous system and hypothermic effects after single oral administration of high doses of\u00a0oseltamivir\u00a0in the rat","volume":"111","author":"Freichel","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/ane.12629-BIB0058|ane12629-cit-0058","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bcpt.12290","article-title":"Oseltamivir\u00a0Blocks Human Neuronal Nicotinic Acetylcholine Receptor-Mediated Currents","volume":"116","author":"Muraki","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/ane.12629-BIB0059|ane12629-cit-0059","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neulet.2007.08.054","article-title":"Neuroexcitatory actions of Tamiflu and its carboxylate metabolite","volume":"426","author":"Izumi","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1111\/ane.12629-BIB0060|ane12629-cit-0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/0960327109102367","article-title":"Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants","volume":"27","author":"Izumi","year":"2008","journal-title":"Hum Exp Toxicol"},{"key":"10.1111\/ane.12629-BIB0061|ane12629-cit-0061","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.brainres.2003.09.068","article-title":"Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice","volume":"995","author":"Crain","year":"2004","journal-title":"Brain Res"},{"key":"10.1111\/ane.12629-BIB0062|ane12629-cit-0062","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2016.1189592","article-title":"The mechanisms of delayed onset type adverse reactions to oseltamivir","author":"Hama","year":"2016","journal-title":"Infect Dis"},{"key":"10.1111\/ane.12629-BIB0063|ane12629-cit-0063","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1742-7843.2012.00889.x","article-title":"High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats","volume":"111","author":"Kimura","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/ane.12629-BIB0064|ane12629-cit-0064","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2220\/biomedres.29.233","article-title":"Effect of a neuraminidase inhibitor (oseltamivir) on mouse jump-down behavior via stimulation of dopamine receptors","volume":"29","author":"Suzuki","year":"2008","journal-title":"Biomed Res"},{"key":"10.1111\/ane.12629-BIB0065|ane12629-cit-0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/bph.12102","article-title":"Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir","volume":"169","author":"Hiasa","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1111\/ane.12629-BIB0066|ane12629-cit-0066","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejphar.2009.11.020","article-title":"In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite","volume":"628","author":"Lindemann","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/ane.12629-BIB0067|ane12629-cit-0067","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1523\/JNEUROSCI.5443-07.2008","article-title":"Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits","volume":"28","author":"Hevers","year":"2008","journal-title":"J Neurosci"},{"key":"10.1111\/ane.12629-BIB0068|ane12629-cit-0068","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1476-5381.1973.tb08243.x","article-title":"Role of 5-hydroxytryptamine in ketamine-induced hypothermia in the rat","volume":"48","author":"Fahim","year":"1973","journal-title":"Br J Pharmacol"},{"key":"10.1111\/ane.12629-BIB0069|ane12629-cit-0069","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-005-0092-6","article-title":"Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man","volume":"182","author":"Aalto","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1111\/ane.12629-BIB0070|ane12629-cit-0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00213-009-1564-x","article-title":"Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans","volume":"206","author":"Freeman","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1111\/ane.12629-BIB0071|ane12629-cit-0071","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/ane.12629-BIB0072|ane12629-cit-0072","first-page":"298","article-title":"Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study","volume":"172","author":"Morgan","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1111\/ane.12629-BIB0073|ane12629-cit-0073","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","article-title":"The novel anticonvulsant drug, gabapentin (Neurontin), binds to the \u03b12\u03b4 subunit of a calcium channel","volume":"271","author":"Gee","year":"1996","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1111\/ane.12629-BIB0074|ane12629-cit-0074","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/mol.59.1.144","article-title":"Gamma-aminobutyric acid\u00a0type\u00a0B\u00a0receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant\u00a0gabapentinaction","volume":"59","author":"Ng","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1111\/ane.12629-BIB0075|ane12629-cit-0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0022-3565(24)29346-0","article-title":"The anticonvulsant, antihyperalgesic agent\u00a0gabapentin\u00a0is an agonist at brain\u00a0gamma-aminobutyric acid\u00a0type\u00a0B\u00a0receptors negatively coupled to voltage-dependent calcium channels","volume":"298","author":"Bertrand","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/ane.12629-BIB0076|ane12629-cit-0076","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0028-3908(97)00189-5","article-title":"Gabapentin\u00a0inhibits calcium currents in isolated rat brain neurons","volume":"37","author":"Stefani","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1111\/ane.12629-BIB0077|ane12629-cit-0077","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1476-5381.1995.tb13265.x","article-title":"Respiratory effects of\u00a0baclofen\u00a0and 3-aminopropylphosphinic acid in guinea-pigs","volume":"114","author":"Hey","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1111\/ane.12629-BIB0078|ane12629-cit-0078","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1542\/peds.101.6.1045","article-title":"Baclofen\u00a0overdose: drug experimentation in a group of adolescents","volume":"101","author":"Perry","year":"1998","journal-title":"Pediatrics"},{"key":"10.1111\/ane.12629-BIB0079|ane12629-cit-0079","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1113\/jphysiol.1992.sp019128","article-title":"Synaptic interaction between medullary respiratory neurones during apneusis induced by NMDA-receptor blockade in cat","volume":"450","author":"Feldman","year":"1992","journal-title":"J Physiol"},{"key":"10.1111\/ane.12629-BIB0080|ane12629-cit-0080","unstructured":"Edwards Et Truffa MM (Division of Drug Risk Evaluation: DDRE) One-Year Post Pediatric Exclusivity Postmarketing Adverse Events Review (Drug: Oseltamivir phosphate) 2005 http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4180b_06_01_Tamiflu%20AE_reviewed.pdf"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12629","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12629\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T23:26:37Z","timestamp":1748993197000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12629","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}